Pharmacyte Biotech Inc (OTCMKTS:PMCB) listed the major objectives that it plans to meet before it initiates Phase IIB trial targeting pancreatic cancer. The company will follow a clinical protocol that will be developed by Contract Research Organization together with company’s team of oncologists. The management termed this protocol as a “recipe” on how the major studies will be performed.
The prime elements that will be covered in protocol are the qualifications required for specific patients to be registered in the study, the way Pharmacyte’s treatment will be used in the “comparator” arm of the trial, the “endpoints”, and the duration and schedule of planned studies, and the data types to be collected to check the endpoints.
In last trading session, the stock price of Pharmacyte declined more than 8% to close the trading session at $0.0830.
Natural Alternatives International, Inc. (NASDAQ:NAII) Registers Complaint Against Creative Compounds Inc.
Natural Alternatives International, Inc. (NASDAQ:NAII) registered a complaint against the firm Creative Compounds Inc. in an attempt to stop it from inappropriately and deliberately trying to deceive company’s prospective and actual clients and wrongfully snooping with its CarnoSyn® beta-alanine operations.
Natural Alternatives markets beta-alanine to clients under the brand CarnoSyn® and has a portfolio of total thirty-four patents in the U.S. and foreign nations linked to beta-alanine. In various scientific studies, CarnoSyn® beta-alanine, when tried as a dietary supplement, has been proven to defer the weariness onset in muscle cells, thus treating muscle soreness and tiredness. It has shown to enhance athletic performance.
Natural Alternatives alleged that in first week of Septembe, Creative Compounds circulated an internet communication to existing clients and prospective clients of beta-alanine making misleading and false statements linked to Creative’s generic beta-alanine and company’s CarnoSyn® beta-alanine.
After recording a strong session on Friday, Uluru Inc (OTCMKTS:ULUR) retreated back yesterday and declined 9.79% to close at $0.350.